Literature DB >> 2285286

Comparative postantibacterial activities of pefloxacin, ciprofloxacin, and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1.

P Rajagopalan-Levasseur1, E Dournon, G Dameron, J L Vilde, J J Pocidalo.   

Abstract

The inhibitory and postantibacterial activities of pefloxacin, ciprofloxacin, and ofloxacin against virulent Legionella pneumophila serogroup 1 were evaluated in cell-free and cellular models. In the absence of macrophages (with the tissue culture medium alone), bacterial numbers remained unchanged at 24 h in the presence of 0.1 microgram of pefloxacin, ciprofloxacin, or ofloxacin per ml and 1.0 microgram of pefloxacin per ml, whereas they were reduced in the presence of 1.0 microgram of ciprofloxacin or ofloxacin per ml. Experiments to evaluate the postantibacterial effects of these drugs were therefore performed with concentrations of 0.1 microgram/ml. In the cell-free model, brief exposure (1 h) of bacteria to each antimicrobial agent resulted in a transient decrease in numbers followed by logarithmic growth. In the cellular model, all three drugs (at 0.1 and 1.0 microgram/ml) inhibited the intracellular multiplication of L. pneumophila. The intracellular postantibacterial effects of 0.1 microgram of pefloxacin, ciprofloxacin, and ofloxacin per ml, which were left in contact with L. pneumophila-infected human macrophages for 24 h, were evaluated at various times after removal of the drugs. Pefloxacin was found to exhibit a significant inhibitory effect at 72 h, whereas following the removal of ciprofloxacin and ofloxacin, rapid bacterial multiplication occurred, leading to the destruction of the macrophage monolayer within 48 h. Thus, while pefloxacin, ciprofloxacin, and ofloxacin all inhibited the multiplication of L. pneumophila in human monocyte-derived macrophages, only pefloxacin exhibited a prolonged postantibacterial effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2285286      PMCID: PMC171914          DOI: 10.1128/AAC.34.9.1733

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Antibiotic susceptibility of Legionella pneumophia Philadelphia-1 in cultured guinea-pig peritoneal macrophages.

Authors:  S Yoshida; Y Mizuguchi
Journal:  J Gen Microbiol       Date:  1984-04

2.  Intracellular multiplication of Legionnaires' disease bacteria (Legionella pneumophila) in human monocytes is reversibly inhibited by erythromycin and rifampin.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

3.  WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

4.  Interactions of antibiotics and phagocytes.

Authors:  W L Hand; N L King-Thompson; T H Steinberg
Journal:  J Antimicrob Chemother       Date:  1983-10       Impact factor: 5.790

5.  Erythromycin uptake and accumulation by human polymorphonuclear leukocytes and efficacy of erythromycin in killing ingested Legionella pneumophila.

Authors:  M F Miller; J R Martin; P Johnson; J T Ulrich; E J Rdzok; P Billing
Journal:  J Infect Dis       Date:  1984-05       Impact factor: 5.226

6.  Liquid medium for growth of Legionella pneumophila.

Authors:  J D Ristroph; K W Hedlund; R G Allen
Journal:  J Clin Microbiol       Date:  1980-01       Impact factor: 5.948

7.  Antibiotic entry into human polymorphonuclear leukocytes.

Authors:  R C Prokesch; W L Hand
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

8.  Uptake of ciprofloxacin by macrophages.

Authors:  C S Easmon; J P Crane
Journal:  J Clin Pathol       Date:  1985-04       Impact factor: 3.411

9.  Susceptibility of Legionella pneumophila to twenty antimicrobial agents.

Authors:  P H Edelstein; R D Meyer
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

10.  Antimicrobial therapy of experimentally induced Legionnaires' disease in guinea pigs.

Authors:  P H Edelstein; K Calarco; V K Yasui
Journal:  Am Rev Respir Dis       Date:  1984-11
View more
  8 in total

1.  In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 2.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila.

Authors:  A L Baltch; R P Smith; W Ritz
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

4.  In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; T Shinzato; E Doyle; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 5.  Treatment of Legionnaires' disease. Current recommendations.

Authors:  J Roig; A Carreres; C Domingo
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

Review 6.  Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.

Authors:  C Chidiac; Y Mouton
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 7.  Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides.

Authors:  G G Zhanel; W A Craig
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

Review 8.  Pefloxacin clinical pharmacokinetics.

Authors:  F Bressolle; F Gonçalves; A Gouby; M Galtier
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.